ASCRS•ASOA SYMPOSIUM & CONGRESS, SAN DIEGO 2015
digital.eyeworld.org
Wednesday, May 10, 2017 EyeWorld Daily News • The official ASCRS•ASOA Show Daily
Dr. Chang speaks at the X-Rounds symposium.
continued on page 2
continued on page 2
Dr. Rubenstein presents his choices for the best cataract papers at the Best of ASCRS 2017.
by Ellen Stodola EyeWorld Senior Staff Writer
Best of ASCRS 2017
by Liz Hillman EyeWorld Staff Writer
Pearls exchanged in rapid-fire X-Rounds
Vance Thompson, MD, Sioux Falls,
South Dakota.
Jonathan Rubenstein, MD,
Chicago, and Michael Knorz, MD,
Mannheim, Germany, presented the
cataract papers.
Dr. Rubenstein's first paper
selection was "Neodymium:YAG
Laser Vitreolysis: A Retrospective
Safety Study." The second paper was
"Long-Term Biocompatibility of a
Modular Intraocular Lens System."
Finally, he chose "DSBCS Versus
ISBCS: Postoperative Refractive
Outcomes." Refractive outcomes
T
he final ASCRS General
Session of the meeting was
the Best of ASCRS 2017 on
Tuesday afternoon. The
session featured presenters
sharing some of the Best Paper of
Session winners in cataract, glauco-
ma, cornea, and refractive from the
meeting.
Eric Donnenfeld, MD, Rock-
ville Centre, New York, and Ronald
Yeoh, MD, Singapore, moderated
the session, with panelists Reay
Brown, MD, Atlanta, Clara Chan,
MD, Toronto, Canada, Boris Mal-
yugin, MD, PhD, Moscow, Russia,
Kevin Miller, MD, Los Angeles, and
Symposium featured
experts giving quick tips
in various categories
T
he X-Men of ASCRS took
to the annual X-Rounds
symposium's stage Tuesday
morning with moderator
Eric "Beast" Donnenfeld,
MD, Rockville Centre, New York,
and panelists David "Wolverine"
Chang, MD, Los Altos, California,
Bonnie "Storm" Henderson, MD,
Boston, John "Professor X" Hova-
nesian, MD, Laguna Hills, Califor-
nia, Stephen "Archangel" Lane,
MD, Stillwater, Minnesota, and
Stephen "Magneto" Slade, MD,
Houston.
In the "What am I doing dif-
ferently?" category, Dr. Chang was
voted the winner by the audience
for sharing his thoughts on switch-
ing to intracameral moxifloxacin
in light of the evidence associating
intraocular vancomycin prophylaxis
with hemorrhagic occlusive retinal
vasculitis. Dr. Chang highlighted
recent data supporting the efficacy
of moxifloxacin. He said he uses
compounded moxifloxacin, but
noted a preparation by Imprimis
Pharmaceuticals (San Diego) and
the use of Vigamox (Novartis, Basel,
Switzerland). The generic version
of Vigamox, Moxeza, should not be
used intracamerally due to preserva-
tives, Dr. Chang said.
